|
JP2019048854A
|
|
Method for production of commercial nanoparticle and microparticle powders
|
|
HK1252214A1
|
|
Diclofenac formulation
|
|
IL257014D0
|
|
A novel formulation of meloxicam
|
|
IL256841D0
|
|
A novel formulation of metaxalone
|
|
AU2016203251A1
|
|
Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
|
|
AU2016200397A1
|
|
A Novel Formulation of Indomethacin
|
|
AU2015261687A1
|
|
A Novel Formulation of Naproxen
|
|
PH12015501811A1
|
|
Production of encapsulated nanoparticles at high volume fractions
|
|
US2015352122A1
|
|
Formulation of meloxicam
|
|
AU2014208310A1
|
|
A Novel Formulation of Diclofenac
|
|
AU2014203359A1
|
|
A Novel Formulation of Meloxicam
|
|
AU2014202776A1
|
|
A Novel Formulation of Indomethacin
|
|
AU2014201967A1
|
|
A Novel Formulation of Naproxen
|
|
AU2013273795A1
|
|
Method for the Preparation of Biologically Active Compounds in Nanoparticle Form
|
|
AU2013273794A1
|
|
NanoParticle Composition(s) and Method for Synthesis Thereof
|
|
AU2012203877A1
|
|
Methods For The Preparation Of Biologically Active Compounds In Nanoparticulate Form
|
|
AU2012201630A1
|
|
NanoParticle Composition(s) and Method for Synthesis Thereof
|
|
KR20160138326A
|
|
Production of encapsulated nanoparticles at high volume fractions
|
|
SG175765A1
|
|
Production of encapsulated nanoparticles at commercial scale
|
|
CN103932988A
|
|
Novel Formulation of Indomethacin
|
